Robert S. Kerbel spends much of his time researching Cancer research, Angiogenesis, Immunology, Internal medicine and Chemotherapy. Robert S. Kerbel combines subjects such as Cell culture, Cell growth, Tyrosine kinase, Tumor progression and Kinase with his study of Cancer research. Robert S. Kerbel interconnects Vascular endothelial growth factor A, Vascular endothelial growth factor, Endothelial stem cell and Receptor tyrosine kinase in the investigation of issues within Angiogenesis.
Robert S. Kerbel has researched Immunology in several fields, including In vitro, Bioinformatics, Progenitor cell, Stem cell and Phenotype. His Internal medicine study combines topics from a wide range of disciplines, such as Cytotoxic T cell, Endocrinology and Oncology. His Chemotherapy research integrates issues from Cancer and Pharmacology.
Robert S. Kerbel mostly deals with Cancer research, Internal medicine, Cancer, Angiogenesis and Immunology. His research integrates issues of Cell culture, Metastasis, Chemotherapy and Tumor progression in his study of Cancer research. His work deals with themes such as Tumor microenvironment and Regimen, which intersect with Chemotherapy.
His Internal medicine study incorporates themes from Endocrinology and Oncology. His Angiogenesis research includes themes of Endothelial stem cell, Vascular endothelial growth factor A, Vascular endothelial growth factor and Blood vessel. His Immunology research includes elements of Phenotype, Drug resistance and Progenitor cell.
The scientist’s investigation covers issues in Internal medicine, Cancer, Cancer research, Oncology and Breast cancer. He usually deals with Internal medicine and limits it to topics linked to Melanoma and Disseminated disease and Brain metastasis. His study looks at the relationship between Cancer and topics such as Pharmacology, which overlap with Camptothecin, Toxicity, Drug resistance, Intensive care medicine and Low-dose chemotherapy.
His Cancer research research is mostly focused on the topic Angiogenesis. His work carried out in the field of Oncology brings together such families of science as Clinical trial, Bevacizumab, Chemotherapy, Adjuvant therapy and Metronomic Chemotherapy. His work deals with themes such as Regimen, Colorectal cancer, Primary tumor and Immunology, which intersect with Breast cancer.
The scientist’s investigation covers issues in Pharmacology, Cancer, Cancer research, Internal medicine and Oncology. His Pharmacology research includes themes of Bevacizumab, Chemotherapy, Metastatic breast cancer, Toxicity and Drug resistance. The study incorporates disciplines such as Disease progression and Pathology in addition to Cancer.
Robert S. Kerbel specializes in Cancer research, namely Neovascularization. His Oncology study integrates concerns from other disciplines, such as Colorectal cancer and Melanoma. His study in Metastasis is interdisciplinary in nature, drawing from both Blood vessel and Angiogenesis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Angiogenesis as a therapeutic target
Napoleone Ferrara;Robert S. Kerbel.
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M.L. Ebos;Christina R. Lee;William Cruz-Munoz;Georg A. Bjarnason.
Cancer Cell (2009)
Clinical translation of angiogenesis inhibitors.
Robert Kerbel;Judah Folkman.
Nature Reviews Cancer (2002)
The anti-angiogenic basis of metronomic chemotherapy
Robert S. Kerbel;Barton A. Kamen.
Nature Reviews Cancer (2004)
Tumor angiogenesis: past, present and the near future.
Robert S. Kerbel.
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
Giannoula Klement;Sylvain Baruchel;Janusz Rak;Shan Man.
Journal of Clinical Investigation (2000)
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Alicia M. Viloria Petit;Janusz Rak;Mien Chie Hung;Patricia Rockwell.
American Journal of Pathology (1997)
Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis
James W. Dennis;Suzanne Laferté;Carol Waghorne;Martin L. Breitman.
Establishment and Characterization of First Trimester Human Trophoblast Cells with Extended Lifespan
Charles H. Graham;Teresa S. Hawley;Robert C. Hawley;John R. MacDougall.
Experimental Cell Research (1993)
Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.
J. Rak;Y. Mitsuhashi;L. Bayko;J. Filmus.
Cancer Research (1995)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: